R&D Pipeline Overview

Through in-licensing from either big pharma/biotech companies or academic institutions, we have established a robust and science-driven portfolio that targets the underlying causes of the various orphan diseases with few or no approved therapeutic options. Our focus is on first-in-class or best-in-class therapeutics that will truly bring meaningful and/or life-saving benefits to patients. We are also leveraging sponsored collaboration and research with universities to help de-risk potential projects before their adoption into our pipeline.

Exploratory

Animal POC

IND Enabling

Phase 1

Phase 2

Phase 3

Peptide

Monoclonal Antibody

Enzyme Replacement

Monoclonal Antibody

Animal POC

Exploratory

IND Enabling

Phase I

Phase II

Phase III

Monoclonal Antibody

Exploratory

Animal POC

IND Enabling

Phase I

Phase II

Phase III

Monoclonal Antibody

Exploratory

Animal POC

Phase I

IND Enabling

Phase II

Phase III

Peptide

Exploratory

Animal POC

IND Enabling

Phase I

Phase II

Phase III

2

1

Undisclosed

LM-070

Enzyme Replacement

Exploratory

Animal POC

Phase I

IND Enabling

Phase II

Phase III

Undisclosed

LM-014

Enzyme Replacement

Exploratory

Animal POC

Phase I

IND Enabling

Phase II

Phase III

LM-014

LM-070

1. Received Orphan Drug Designation (ODD) from both FDA & European Commission.

2. Received Rare Pediatric Designation (RPD) from FDA.

Treating Orphan Diseases Having Few or No Therapeutic Options.

map.png

Redwood City, CA, USA

map.png

Taipei, Taiwan

©2020 BY LIFEMAX HEALTHCARE INTERNATIONAL